| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.TP.0000071362.99021.D9 |
| P698 | PubMed publication ID | 12865797 |
| P50 | author | David E. Kleiner | Q41449492 |
| P2093 | author name string | Allan D Kirk | |
| David M Harlan | |||
| Roslyn B Mannon | |||
| Steven C Hoffmann | |||
| S John Swanson | |||
| Douglas A Hale | |||
| Douglas K Tadaki | |||
| Linda K Cendales | |||
| Robert L Kampen | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| antibody | Q79460 | ||
| P304 | page(s) | 120-129 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). | |
| P478 | volume | 76 |
| Q36079991 | A causal link between lymphopenia and autoimmunity |
| Q33602527 | A comprehensive review of immunosuppression used for liver transplantation |
| Q37282011 | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab |
| Q46793006 | A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation |
| Q34906283 | A shift towards pro-inflammatory CD16+ monocyte subsets with preserved cytokine production potential after kidney transplantation. |
| Q83396334 | Abrogation of antibodies improves outcome of renal transplantation |
| Q45875526 | Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis |
| Q33567138 | Acquired immunologic tolerance: with particular reference to transplantation |
| Q37387510 | Acute transplant glomerulopathy with monocyte rich infiltrate |
| Q46485560 | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| Q46569182 | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial |
| Q51318263 | Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. |
| Q51749477 | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| Q39513891 | Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness |
| Q36880514 | Alemtuzumab as compared to alternative contemporary induction regimens. |
| Q40217347 | Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study. |
| Q37810958 | Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation |
| Q46702767 | Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results |
| Q43834374 | Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results |
| Q42150369 | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes |
| Q46245992 | Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells |
| Q36818003 | Alemtuzumab induction in pediatric kidney transplantation. |
| Q42876591 | Alemtuzumab induction therapy in solid organ transplantation |
| Q46369185 | Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation |
| Q42411640 | Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation |
| Q34187625 | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody |
| Q42226145 | Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience |
| Q39991648 | Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation? |
| Q38392458 | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management |
| Q34201121 | Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation |
| Q90604795 | B cell reconstitution following alemtuzumab induction under a belatacept-based maintenance regimen |
| Q42221525 | B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. |
| Q38050398 | B cells and antibodies in multiple sclerosis pathogenesis and therapy |
| Q37782255 | B cells and transplantation tolerance |
| Q36429791 | B cells: a rational target in alloantibody-mediated solid organ transplantation rejection |
| Q36925946 | BAFF is increased in renal transplant patients following treatment with alemtuzumab |
| Q33364817 | Benefit-risk assessment of sirolimus in renal transplantation |
| Q36235319 | Bidirectional alloreactivity: A proposed microchimerism-based solution to the NIMA paradox |
| Q26829578 | Biologics in organ transplantation |
| Q36494225 | Biologics in the prevention and treatment of graft rejection |
| Q38180358 | Biomarkers for kidney transplant rejection |
| Q36251298 | CAMPATH: from concept to clinic |
| Q46569157 | Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. |
| Q44891446 | Campath induction in HCV and HCV/HIV-seropositive kidney transplant recipients |
| Q50866852 | Cancer risk with alemtuzumab following kidney transplantation. |
| Q34761336 | Challenges in pediatric renal transplantation |
| Q36368260 | Challenges in therapeutic strategies for transplantation: where now from here? |
| Q50091194 | Change in lymphocyte to neutrophil ratio predicts acute rejection after heart transplantation. |
| Q38338061 | Circulating biomarkers of tolerance |
| Q37233443 | Clinical operational tolerance after kidney transplantation: a short literature review |
| Q35991484 | Clinical operational tolerance after renal transplantation: current status and future challenges. |
| Q38080021 | Clinical operational tolerance in liver transplantation: state-of-the-art perspective and future prospects |
| Q37843801 | Clinical transplantation tolerance |
| Q57702538 | Clinical update: immunosuppression minimisation |
| Q36062030 | Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens |
| Q42160171 | Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal. |
| Q36708274 | Composite tissue allotransplantation immunology |
| Q39025865 | Crosstalk Between T and B Cells in the Germinal Center After Transplantation. |
| Q38820685 | Current challenges and future directions for liver transplantation. |
| Q37900647 | Current landscape for T-cell targeting in autoimmunity and transplantation |
| Q40122855 | Cytomegalovirus appendicitis after hematopoietic stem cell transplantation. |
| Q38335413 | Dendritic cells and innate immunity in kidney transplantation |
| Q37203108 | Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft |
| Q42634204 | Development of a humanized mouse model to study the role of macrophages in allograft injury |
| Q53595595 | Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. |
| Q37308415 | Differential effects of donor-specific alloantibody |
| Q37423540 | Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. |
| Q50456082 | Down-regulated expression of monocyte/macrophage major histocompatibility complex receptors in human and mouse monocytes by expression of their ligands. |
| Q34561556 | Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy |
| Q37201405 | Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. |
| Q39363717 | Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction. |
| Q37978779 | Emerging uses for pediatric hematopoietic stem cells |
| Q35795851 | Evaluating the validity of animal models for research into therapies for immune-based disorders |
| Q37418390 | Evolving trends in induction therapy |
| Q35032603 | Five-year outcomes with alemtuzumab induction after lung transplantation |
| Q28069956 | Genetic barriers in transplantation medicine |
| Q84409748 | Glomerulitis during acute cellular rejection may be a surrogate marker of vasculitis in renal allografts--better index for diagnosis of vasculitis |
| Q36078907 | Hand transplantation. A future clinical option? |
| Q80887450 | Heart allograft acceptance induced by anti-CD3 antibody in high-responder rats: effect on foxp3 and cytokine expression and graft infiltration |
| Q33374374 | Hemolytic uremic syndrome following Campath-1H induction |
| Q46797116 | Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression |
| Q37066280 | Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT |
| Q37395089 | Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation |
| Q89755936 | Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease and Regenerative Medicine |
| Q58122073 | IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade |
| Q38592500 | IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. |
| Q47404836 | IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection. |
| Q34622395 | Identification of gene markers for the prediction of allograft rejection or permanent acceptance. |
| Q38064621 | Immune tolerance and transplantation |
| Q36909564 | Immune tolerance: mechanisms and application in clinical transplantation |
| Q37400370 | Immunologic Basis of Graft Rejection and Tolerance Following Transplantation of Liver or Other Solid Organs |
| Q37026155 | Immunologic Monitoring of T-Lymphocyte Subsets and Hla-Dr-Positive Monocytes in Kidney Transplant Recipients: A Prospective, Observational Cohort Study. |
| Q34027642 | Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study |
| Q36586891 | Immunosuppressive preconditioning or induction regimens : evidence to date |
| Q36595129 | Immunotherapy for De Novo renal transplantation: what's in the pipeline? |
| Q27690246 | Improving the safety of tolerance induction: chimerism and cellular co-treatment strategies applied to vascularized composite allografts |
| Q55385759 | Individualizing immunosuppression in lung transplantation. |
| Q37768806 | Induction of tolerance in clinical kidney transplantation |
| Q46070770 | Induction of tolerance in solid organ transplantation: the rationale to develop clinical protocols in liver transplantation |
| Q35038079 | Induction of transplantation tolerance in non-human primate preclinical models |
| Q37996078 | Induction therapy in renal transplant recipients: how convincing is the current evidence? |
| Q37025883 | Induction therapy in renal transplantation : an overview of current developments |
| Q57053368 | Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders |
| Q38341632 | Innate immunity in solid organ transplantation: an update and therapeutic opportunities |
| Q37864689 | Innate immunity in transplant tolerance and rejection |
| Q36501667 | Is clinical tolerance realistic in the next decade? |
| Q43151563 | Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells |
| Q37088225 | Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome |
| Q41161206 | Kidney after Extrarenal Transplantation - The Impact of Alemtuzumab Induction |
| Q34546898 | Kidney after nonrenal transplantation-the impact of alemtuzumab induction |
| Q34304820 | Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath |
| Q35153318 | Late kidney allograft loss: what we know about it, and what we can do about it |
| Q41897278 | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy |
| Q35881889 | Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation |
| Q57413750 | Longitudinal Analysis of Whole Blood Transcriptomes to Explore Molecular Signatures Associated with Acute Renal Allograft Rejection |
| Q41947325 | Longitudinal analysis of whole blood transcriptomes to explore molecular signatures associated with acute renal allograft rejection |
| Q37993873 | Lymphodepletion and homeostatic proliferation: implications for transplantation |
| Q38118743 | Lymphodepletional strategies in transplantation. |
| Q26998846 | Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders? |
| Q35999549 | Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer? |
| Q38753494 | Memory T cells in organ transplantation: progress and challenges |
| Q33708195 | Memory T-cell-specific therapeutics in organ transplantation |
| Q37262425 | Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation |
| Q46835830 | Modern immunosuppression following renal transplantation. Standard or tailor made? |
| Q57202180 | Modulation of Innate Immune Cells to Create Transplant Tolerance |
| Q33617204 | Monocyte infiltration and kidney allograft dysfunction during acute rejection |
| Q37565855 | Monocytes/macrophages in renal allograft rejection |
| Q52672096 | Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients. |
| Q42016732 | NK cells are required for costimulatory blockade induced tolerance to vascularized allografts |
| Q37662989 | Old game, new players: Linking classical theories to new trends in transplant immunology |
| Q36152685 | Organ transplantation--how much of the promise has been realized? |
| Q53861449 | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. |
| Q42502255 | Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation |
| Q40159236 | Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation |
| Q38507644 | Pediatric liver transplant with Campath 1H induction--Preliminary report |
| Q35611179 | Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction |
| Q37362699 | Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys |
| Q36769110 | Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients |
| Q35499848 | Pre-transplant plasma Torque Teno virus load and increase dynamics after lung transplantation |
| Q41924854 | Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review |
| Q84588320 | Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation |
| Q53145957 | Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. |
| Q38187176 | Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy |
| Q43432898 | Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab |
| Q37738204 | Renal allograft granulomatous interstitial nephritis: observations of an uncommon injury pattern in 22 transplant recipients. |
| Q41810263 | Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy |
| Q36895544 | Renal transplantation in high-risk patients |
| Q34412887 | Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. |
| Q39409394 | Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. |
| Q35963432 | Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation |
| Q24240985 | Steroid avoidance or withdrawal for kidney transplant recipients |
| Q53890647 | Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. |
| Q40237893 | Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. |
| Q35990853 | Strategies for minimizing immunosuppression in kidney transplantation |
| Q35841386 | Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors |
| Q38750505 | Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation |
| Q37531824 | The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival |
| Q36889956 | The arduous road to achieving an immunosuppression-free state in kidney transplant recipients |
| Q36682686 | The classification and treatment of antibody-mediated renal allograft injury: where do we stand? |
| Q35779272 | The clinical application of monoclonal antibody therapies in renal transplantation |
| Q37112199 | The effects of antibody treatment on regulatory CD4(+)CD25(+) T cells |
| Q36570565 | The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation |
| Q34613973 | The evolving role of alemtuzumab (Campath-1H) in renal transplantation. |
| Q38747419 | The immunological function of CD52 and its targeting in organ transplantation |
| Q37896918 | The innate immune system in transplantation. |
| Q35893645 | The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials |
| Q46340832 | The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation |
| Q51966817 | The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. |
| Q37690953 | The yin and yang of B cells in graft rejection and tolerance |
| Q90704825 | There Is High Sensitive and Specific Correlation Between Frozen and Permanent Sections in Renal Transplant Biopsies |
| Q35893656 | Tolerance induction in clinical transplantation |
| Q37288737 | Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. |
| Q83956260 | Towards the identification of biomarkers of transplantation tolerance |
| Q90332833 | Trained immunity in organ transplantation |
| Q34438306 | Transient lymphopenia breaks costimulatory blockade-based peripheral tolerance and initiates cardiac allograft rejection |
| Q91554792 | Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation |
| Q36447590 | Transplant tolerance in non-human primates: progress, current challenges and unmet needs |
| Q37111904 | Treating multiple sclerosis with monoclonal antibodies |
| Q34359751 | Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus |
| Q38769922 | Use of polyclonal/monoclonal antibody therapies in transplantation |
| Q36750090 | Use of sirolimus in solid organ transplantation |
Search more.